This bill (S 2244) changes Medicaid eligibility rules for non-qualified aliens by moving the effective date for excluding them from Medicaid from October 2026 to July 4, 2025. It specifically targets states that provide health benefits or financial assistance (from state funds) to non-qualified aliens who are not lawfully residing children or pregnant women eligible for Medicaid. The bill defines "specified states" as those offering such coverage to these individuals, triggering adjustments to federal Medicaid funding (FMAP) for those states. This directly affects Medicaid programs in states providing health coverage to non-qualified aliens and impacts non-citizen residents who would lose Medicaid eligibility under the new timeline.
This bill clarifies the "public charge" rule for immigration, defining it as an immigrant likely to receive public benefits for more than 12 months in any 36-month period. It specifically lists benefits to count - including Medicaid (excluding emergency care for children/pregnant women), food stamps, housing aid, and health subsidies - and requires sponsors to prove financial ability at 125% of the federal poverty line. Applicants deemed likely to become a public charge may need to post a $10,000 bond, forfeitable if they receive benefits within 10 years. The rule applies to all visa and status applications filed after the effective date, excluding refugees, asylees, and military families.
HR 6420 (the ACCESS Act) defines and regulates "short-term limited duration insurance" (STLDI) as health coverage with a contract term under 12 months and total duration under 3 years, including renewals. The bill changes existing health care rules to allow STLDI to be marketed as a temporary coverage option during transitions like job changes, specifically for small businesses and workers needing flexible, affordable plans while avoiding full-year coverage requirements. This directly affects small business owners and employees seeking portable, low-cost health insurance during coverage gaps, without requiring the full benefits of standard plans.
HRES 694 is a non-binding House resolution calling on the Centers for Medicare & Medicaid Services (CMS) to halt a pilot program using artificial intelligence to decide Medicare coverage for medical services. It directly affects seniors who rely on Medicare, as the resolution argues AI-driven coverage decisions could jeopardize their access to critical healthcare. The resolution expresses the House's "sense" that CMS should not proceed with this AI evaluation method, referencing CMS's June 2025 announcement of the pilot. As a resolution, it does not create new law but urges CMS to pause the program.
This bill restricts health savings accounts (HSAs), Archer MSAs, health flexible spending accounts, and health reimbursement arrangements from covering most abortion expenses. It allows exceptions only for abortions resulting from rape or incest, or when a pregnancy poses a life-endangering risk to the woman (as certified by a physician). The law amends tax code provisions to exclude non-exempt abortion costs from being treated as qualified medical expenses for tax purposes. These changes take effect for taxable years beginning after December 31, 2025, directly affecting individuals using these specific tax-advantaged health accounts.
This bill reauthorizes federal funding for tick-borne disease programs under the Public Health Service Act. It reduces annual funding levels for two key programs: $8 million per year (from $10 million) for the National Strategy and Regional Centers of Excellence (2026-2030), and $19 million per year (from $20 million) for health department support programs (2026-2030). These changes extend existing programs through 2030 with adjusted funding amounts. The bill directly affects public health programs and state/local health departments addressing tick-borne diseases like Lyme disease.
This bill blocks the implementation of a new federal staffing rule for nursing homes, specifically halting the May 2024 rule requiring minimum staffing levels in long-term care facilities. It directly affects rural nursing facilities and their workforce by preventing a regulation that could increase operational demands. The bill creates a 17-member advisory panel with mandatory rural representation to study nursing home staffing shortages, analyze regulatory impacts, and recommend solutions to strengthen the workforce. The panel must submit annual reports to Congress and the public, focusing on barriers to care access in rural and underserved areas. This is a procedural measure stopping a specific rule while establishing a review mechanism, not a direct funding or service change.
HR 729, the Teleabortion Prevention Act of 2025, prohibits healthcare providers from administering chemical abortions (using drugs to terminate pregnancy) via telehealth or remote means without being physically present during the procedure. It requires providers to physically examine the patient, be present at the location of the abortion, and schedule a follow-up visit within 14 days. The bill directly affects healthcare providers offering telemedicine abortion services, imposing fines up to $1,000 or up to 2 years in prison for violations. Exceptions apply for life-threatening medical emergencies, and the law explicitly excludes treatment for verified ectopic pregnancies. This bill targets the remote provision of abortion drugs, making in-person provider presence mandatory for such procedures.
HRES 803 is a non-binding resolution urging the FDA to reassess the safety of all chemical abortion drugs based on recent independent studies. It specifically requests the FDA reevaluate safety data and publicly release a full safety review including real-world complications. The resolution does not change laws or create new requirements but asks the FDA to consider findings that claim complication rates are 22 times higher than current reports. This resolution directly addresses the FDA's regulatory oversight of these drugs, not other entities or policies.
HR 2197, the "No 340B Savings for Transgender Care Act," prohibits covered entities participating in the federal 340B drug pricing program from using savings from discounted drug purchases to pay for specific transgender healthcare services. The bill amends the Public Health Service Act to ban using 340B savings for sex reassignment surgeries or hormone treatments provided "for the purpose of gender alteration" of transgender individuals. This directly affects hospitals and clinics enrolled in the 340B program, restricting how they allocate funds saved through the program’s discounted drug pricing. The key provision is a targeted restriction on fund usage, not a ban on providing the medical services themselves. The bill focuses on reallocating program savings away from these specific care types.
